Oncolytic bacteria become a new direction for cancer immunotherapy!

Recent popular reports from Yimaike ★ "Self-delivery" RNAi therapy targeting PD-1, with powerful tumor control and tumor microenvironment regulation capabilitiesYimai Meng broke the news ★Excellent opening ceremonyCongratulations on BPIT 2021 Biopharmaceutical Innovation Technology Conference in Minhang Successfully concluded April 13, 2021/eMedClub News/-April 9-10, the two-day BPIT 2021 Biopharmaceutical Innovation Technology Conference was grandly held in Shanghai, and nearly one hundred authoritative leaders of bio-innovative drugs , Hundreds of leading biopharmaceutical companies, and more than a thousand peers in the pharmaceutical field gathered in Shanghai to participate in this grand event in the biopharmaceutical industry.

 Hong Kong Pharmaceuticals Oncolytic Biopharmaceutical Co.
, Ltd.
also made a shining appearance at this conference.
Its world's first oncolytic bacterial carrier YB1 caused a huge response at the exhibition, attracting a wide range of pharmaceutical industry peers, professional investment professionals and biomedical research enthusiasts.
Attention and lively discussion, let Hong Kong Medicine Oncolytic Biopharmaceuticals become one of the star companies of this conference.

 YB1——The world's first oncolytic bacterial carrier Hong Kong drug Oncolytic Biopharmaceuticals focuses on the research and development of innovative drugs in the field of targeted tumor therapy.
It has a world-leading oncolytic bacterial technology platform based on synthetic biology and is committed to providing revolutionary products to the world.
Cancer immunotherapy solutions.

 In 2011, the founder of the company, Dr.
Bin Yu from the University of Hong Kong and his team implemented the Salmonella Lambda-RED high-efficiency programming technology for the first time in their research, and established the basis for the transformation of Salmonella synthetic biology.

After more than 10 years of development cycle, Dr.
Yu Bin and his R&D team successfully invented a genetically programmed, oncolytic strain of Salmonella typhimurium (Salmonella typhimurium) and named it YB1.

At present, more oncolytic viruses are seen in the domestic and foreign markets.
The major pharmaceutical companies have very fierce competition in the layout of oncolytic virus immunotherapy.
The YB1 of Hong Kong-based Oncolytic Biopharmaceuticals is the world’s first oncolytic bacterial carrier.
It is also the only tumor-targeting oncolytic bacterial carrier in the world with independent technology patents.

 The oncolytic bacterial immunotherapy based on YB1 formed by Hong Kong's Oncolytic Biopharmaceuticals represents the true blue ocean market in the current tumor immunotherapy field and has a huge prospect.

 Incarnate as a "biological missile", YB1 has a strong drug delivery capability.
In addition to oncolytic properties, YB1 also has a strong drug carrying capability.

Research by Dr.
Yu Bin’s team has shown that the oncolytic bacteria YB1 as a carrier can efficiently deliver and carry "weapons" including antibodies, mRNA, protein drugs, and oncolytic viruses, and can be transformed into "biological missiles" to precisely target the hypoxic area in the center of the tumor , And achieve a large number of replication and amplification within the tumor, greatly increasing the concentration of YB1 vector at the target site of solid tumors.

 YB1 releases a variety of therapeutic "warhead" drugs after reaching the inside of the tumor, which can inhibit tumor growth and cause tumor dissolution, and at the same time can eliminate tumor metastasis, and has great clinical application potential.

 The YB1 tumor-oriented drug delivery system of Hong Kong Oncolytic Biopharmaceuticals exerts its oncolytic effect in three stages after injection: 30 minutes after injection is the guidance period, at this stage YB1 can continuously scan the surrounding environment through its precise targeting Find the location of the tumor based on the oxygen concentration; if the tumor area is not found within 30 minutes, YB1 will start the self-destruction program, which will not cause damage to the body.

 Within 24 hours after injection, the tumor is locked in.
At this stage, YB1 first recognizes the hypoxic area of ​​the tumor (oxygen concentration <0.
5%), and activates the survival mode within 24 hours, and begins to destroy the tumor’s vascular and circulatory system; at the same time, YB1 will A large amount of self-replication inside the tumor increases its number in the tumor area.

 24 hours after injection is the period of weapon release.
In this stage, YB1 will continue to self-replicate to form a community, and activate the YB1 synthesis weapon mechanism to release the antibodies, protein drugs, mRNA, oncolytic viruses, etc.
it carries, forming a chain reaction.
It can cause tumor cell death to produce oncolytic effect; at the same time, YB1 can activate natural immune NK cells and activate NK cells to kill metastatic tumor cells.

 How to achieve tumor targeting? As a bacterial carrier for tumor-targeted drug delivery, YB1's tumor targeting is mainly based on the important characteristics of the solid tumor microenvironment: there is a hypoxic area in the center of the tumor, and the oxygen concentration is less than 0.
5%, which is obviously different from Normal organs (oxygen concentration between 1-5%); In addition, solid tumors have poor blood circulation, resulting in strong tolerance to various chemotherapeutic drugs, antibody drugs, and cellular drugs.

 Since the hypoxia characteristics of tumors are obvious, if the facultative anaerobic Salmonella can be engineered in some way so that it can only survive when the oxygen content is less than 0.
5%, the purpose of targeting tumors can be achieved, and damage to the tumor can be avoided.
Damage to normal tissues.

 As mentioned above, in 2011, Dr.
Yu Bin and his team realized the Salmonella Lambda-RED high-efficiency programming technology for the first time in their research, and established the basis for the transformation of Salmonella synthetic biology.

Through synthetic biology modification, YB1 can achieve specific targeting of tumor hypoxia, and it will automatically lyse in an environment where oxygen exceeds 0.
5% to achieve tumor-specific hoarding and attack; in the case of hypoxia (<0.
5%), YB1 It reproduces itself quickly and releases the drugs it carries to attack the tumor.

 YB1 Oncolytic Bacterial Immunotherapy: An important research direction of cancer immunotherapy at the forefront of the times.
For a long time, almost all malignant tumors have been collectively referred to as "cancer", and cancer is generally regarded by humans because of its extremely high mortality rate.
The terrifying life-threatening "terminal illness".

Tumor metastasis is one of the main causes of cancer-related deaths.
At present, there is still an urgent need to find more targeted drugs that can effectively inhibit tumor metastasis.

 In the face of cancer, most people think that surgery, chemotherapy or radiation therapy, and the latest immunotherapy based on immune checkpoint antibodies are the few possible solutions.

But in fact, not all cancer patients are suitable for surgery, and cancer metastasis can also cause the failure of surgical treatment; chemotherapy or radiation therapy may cause great damage to normal organs and small effects on the cancer site; and immune checkpoints The average response rate of antibodies is also low.

 The core reason for the above treatment dilemma is that most tumors (more than 90%) will form solid tumors, and a distinctive feature of solid tumors is that a very special hypoxic zone is formed in the center of the tumor, which is different from the hypoxic zone.
The organization of normal people.

Tumor cells in hypoxia may exhibit inhibition of cell cycle progression and proliferation, and therefore can relatively tolerate many anti-cancer drugs targeting rapidly dividing cells; in addition, most drugs are administered intravenously or orally.
The concentration of the drug at the tumor site becomes very limited, and the side effects are amplified.
This is a common problem of traditional drug types.

 The intentional application of bacteria in cancer treatment can be traced back to the late nineteenth century, and there are even earlier anecdotal reports of the efficacy of bacteria in cancer treatment.
The first reported use of bacteria (Streptococcus pyogenes) to treat inoperability The sarcoma can significantly reduce tumor and lymph node metastasis.

The current hot oncolytic viruses are also similar technologies.
Viral vectors are currently the most widely used delivery vehicles, but they are not easy to eliminate, they are also potentially tumorigenic, and their effectiveness is relatively limited.

 Therefore, non-viral vectors (such as bacterial vectors) with greater efficacy and safe handling are a very promising solution for the development of new delivery systems.

The YB1 developed by Hong Kong Oncolytic Biopharmaceuticals is not only the world's first oncolytic bacterial carrier, its YB1-based oncolytic bacterial immunotherapy is also an important research direction in the field of cancer immunotherapy that is truly at the forefront.

 YB1: It is not only in tumor treatment, but also has broad technical expansibility.
YB1 is used in tumor immunotherapy and can carry a variety of drugs.
The indications include sarcoma, melanoma, PDL1-positive melanoma and other solid tumors, etc.
The product pipeline layout is very rich .

It is reported that YB1's existing multiple product pipelines are currently in the pre-clinical testing stage, and its human clinical trials will soon be promoted.

 In addition to carrying a variety of warhead drugs, YB1 also has broad and powerful technical expansibility.

The research of Dr.
Yu Bin's team found that YB1 can also adopt antibody-drug conjugate (ADC) mode: YB1-ADC.

This type of product is expressed through YB1 internal gene regulation, and presents the antibody sequence to the appearance of YB1 to realize the antibody coupling effect, and has now entered the preclinical research and development stage.

 Outside the field of tumor immunotherapy, YB1 can also be used for various thrombosis treatments.

It is understood that YB1-rt-PA will be the first-generation targeted thrombus ablation product of Hong Kong-based Oncolytic Biopharmaceuticals.
The main feature is that it is carried by YB1 and releases Urokinase at the location of the thrombus to achieve rapid targeted release of thrombolytic drugs.
effect.

 It is worth mentioning that YB1 has been successfully used in the treatment of primary cancers in pets.
In 2016, the first pet dog with malignant sarcoma, Noopy, was cured after YB1 treatment.
By 2020, Hong Kong-based Oncolytic Biopharmaceuticals Completed the pet cancer YB1 clinical study, more than 100 pet dogs with cancer were enrolled, and Noopy also achieved 4 years of cancer-free survival.

 In 2021, Hong Kong Medicines Oncolytic Biopharmaceuticals established a strategic partnership with the University of Hong Kong (HKU), and obtained the exclusive authorization and commercial development rights for all YB1 patents.

In the future, Hong Kong Medicine Oncolytic Biopharmaceuticals will continue to explore in the field of targeted tumor therapy, accelerate the human clinical trial research of YB1 oncolytic bacterial therapy, and actively promote its multi-pipeline technology expansion and commercial application development process, and is committed to Contribute to the research and development of innovative drugs for humans to fight cancer and tumor treatment.

For more information about Hong Kong medicine oncolytic biopharmaceuticals and oncolytic bacterial carrier YB1, please visit www.
yb1bio.
com or contact gary@awsg.
com/ 18101137302.

Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions.

In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.